Sleeping Beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Deniger, Drew C ^a,b,d   Yu, Jianqiang ^c   Huls, M Helen ^a   Figliola, Matthew J ^a   Mi, Tiejuan ^a   Maiti, Sourindra N ^a   Widhopf, George F ^c   Hurton, Lenka V ^a,b   Thokala, Radhika ^a,b   Singh, Harjeet ^a   Olivares, Simon ^a   Champlin, Richard E ^a   Wierda, William G ^a   Kipps, Thomas J ^c   Cooper, Laurence J N ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 21; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1; UNCLASSIFIED DRUG; CYTOKINE; HYBRID PROTEIN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; TRANSPOSON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL EXPANSION; CHIMERA; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA TRANSPOSITION; FEMALE; FLOW CYTOMETRY; GAMMA IRRADIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSPOSON; TUMOR CELL; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; LEUKEMIA; METABOLISM; PANCREAS TUMOR; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; DNA TRANSPOSABLE ELEMENTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-GAMMA; LEUKEMIA; MICE; PANCREATIC NEOPLASMS; PHENOTYPE; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 84933056343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128151     Document Type: Article

References (52)

1. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010; 116(7):1035-44. Epub 2010/05/05. doi: blood-2010-01-043737 [pii]doi: 10.1182/blood-2010-01-043737 PMID: 20439624; PubMed Central PMCID: PMC2938125.
2. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest. 2007; 117(5):1204-12. Epub 2007/05/04. doi: 10.1172/JCI31446 PMID: 17476350; PubMed Central PMCID: PMC1857246.
3. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-18. Epub 2013/03/27. doi: 10.1056/NEJMoa1215134 PMID: 23527958.
4. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011; 118(18):4817-28. Epub 2011/08/19. doi: 10.1182/blood-2011-04-348540 PMID: 21849486; PubMed Central PMCID: PMC3208293.
5. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012; 119(12):2709-20. Epub 2011/12/14. doi: 10.1182/blood-2011-10-384388 PMID: 22160384; PubMed Central PMCID: PMC3327450.
6. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95: ):95ra73. Epub 2011/08/13. doi: 3/95/95ra73 [pii]doi: 10.1126/scitranslmed.3002842 PMID: 21832238.
7. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. Epub 2011/08/13. doi: 10.1056/NEJMoa1103849 PMID: 21830940.
8. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013; 122(17):2965-73. Epub 2013/09/14. doi: 10.1182/blood-2013-06-506741 PMID: 24030379; PubMed Central PMCID: PMC3811171.
9. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. Epub 2014/10/16. doi: 10.1056/NEJMoa1407222 PMID: 25317870.
10. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967):517-28. doi: 10.1016/S0140-6736(14) 61403-3 PMID: 25319501.
11. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. Epub 2005/06/03. doi: 10.1172/JCI24480 PMID: 15931392; PubMed Central PMCID: PMC1137001.
12. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014; 41(1):116-26. Epub 2014/07/19. doi: 10.1016/j.immuni.2014.05.018 PMID: 25035956.
13. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005; 142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x PMID: 16178850; PubMed Central PMCID: PMC1809480.
14. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010; 18(4):666-8. Epub 2010/04/02. doi: 10.1038/mt.2010.31 PMID: 20357779; PubMed Central PMCID: PMC2862525.
15. Nomi M, Oishi I, Kani S, Suzuki H, Matsuda T, Yoda A, et al. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol. 2001; 21(24):8329-35. Epub 2001/11/20. doi: 10.1128/MCB.21.24.8329-8335.2001 PMID: 11713269; PubMed Central PMCID: PMC99997.
16. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008; 14(2):396-404. Epub 2008/01/29. doi: 10.1158/1078-0432.CCR-07-1823 PMID: 18223214.
17. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer. 2008; 123(5):1190-5. Epub 2008/06/12. doi: 10.1002/ijc.23587 PMID: 18546292.
18. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A. 2008; 105(8):3047-52. Epub 2008/02/22. doi: 10.1073/pnas.0712148105 PMID: 18287027; PubMed Central PMCID: PMC2268582.
19. Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012; 7(3):e31127. Epub 2012/03/10. doi: 10.1371/journal.pone.0031127 PMID: 22403610; PubMed Central PMCID: PMC3293865.
20. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012; 181(6):1903-10. Epub 2012/10/09. doi: 10.1016/j.ajpath.2012.08.024 PMID: 23041612; PubMed Central PMCID: PMC3509760.
21. Rebagay G, Yan S, Liu C, Cheung NK. ROR1 and ROR2 in Human 1Malignancies: Potentials for Targeted Therapy. Front Oncol. 2012; 2:34. Epub 2012/06/02. doi: 10.3389/fonc.2012.00034 PMID: 22655270; PubMed Central PMCID: PMC3356025.
22. Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, et al. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy. Proc Natl Acad Sci U S A. 2014; 111 (48):17266-71. doi: 10.1073/pnas.1419599111 PMID: 25411317; PubMed Central PMCID: PMC4260559.
23. Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, et al. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One. 2012; 7(12):e52655. Epub 2013/01/04. doi: 10.1371/journal.pone.0052655 PMID: 23285131; PubMed Central PMCID: PMC3527582.
24. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. ROR1 is expressed on hematogones (nonneoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011; 35(10):1390-4. Epub 2011/08/05. doi: 10.1016/j.leukres.2011.06.021 PMID: 21813176; PubMed Central PMCID: PMC3163753.
25. Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, et al. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res. 2015; 3 (2):206-16. doi: 10.1158/2326-6066.CIR-14-0163 PMID: 25355068; PubMed Central PMCID: PMC4324006.
26. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010; 18(4):674-83. Epub 2010/01/28. doi: mt20102 [pii]doi: 10.1038/mt.2010.2 PMID: 20104209; PubMed Central PMCID: PMC2862530.
27. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013; 161(4):265-83. Epub 2013/01/15. doi: 10.1016/j. trsl.2012.12.005 PMID: 23313630; PubMed Central PMCID: PMC3602164.
28. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, et al. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013;(72: ):e50070. Epub 2013/02/15. doi: 10.3791/50070 PMID: 23407473; PubMed Central PMCID: PMC3596954.
29. Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013; 36(2):112-23. Epub 2013/02/05. doi: 10.1097/CJI.0b013e3182811ce9 PMID: 23377665; PubMed Central PMCID: PMC3568214.
30. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS One. 2013; 8(5):e64138. Epub 2013/06/07. doi: 10.1371/journal.pone.0064138 PMID: 23741305; PubMed Central PMCID: PMC3669363.
31. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014; 257(1):181-90. Epub 2013/12/18. doi: 10.1111/imr.12137 PMID: 24329797.
32. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Res. 2011; 71(10):3516-27. Epub 2011/05/12. doi: 0008-5472.CAN-10-3843 [pii]doi: 10.1158/0008-5472.CAN-10-3843 PMID: 21558388; PubMed Central PMCID: PMC3096697.
33. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008; 68(8):2961-71. Epub 2008/04/17. doi: 68/8/2961 [pii]doi: 10.1158/0008-5472.CAN-07-5600 PMID: 18413766; PubMed Central PMCID: PMC2424272.
34. Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012; 22(5):656-67. Epub 2012/11/17. doi: 10.1016/j.ccr.2012.08.027 PMID: 23153538; PubMed Central PMCID: PMC3500515.
35. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone MC, et al. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther. 2007; 15 (5):981-8. Epub 2007/03/22. doi: 10.1038/mt.sj.6300134 PMID: 17375070.
36. O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012; 2:249. Epub 2012/02/23. doi: 10.1038/srep00249 PMID: 22355761; PubMed Central PMCID: PMC3278154.
37. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, et al. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014; 20 (22):5708-19. doi: 10.1158/1078-0432.CCR-13-3451 PMID: 24833662; PubMed Central PMCID: PMC4233015.
38. Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013; 21(3):638-47. Epub 2013/01/09. doi: 10.1038/mt.2012.267 PMID: 23295945; PubMed Central PMCID: PMC3589159.
39. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010; 116(22):4532-41. Epub 2010/08/13. doi: 10.1182/blood-2010-05-283309 PMID: 20702778; PubMed Central PMCID: PMC2996114.
40. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012; 23(5):444-50. Epub 2011/11/24. doi: 10.1089/hum.2011.167 PMID: 22107246; PubMed Central PMCID: PMC3360496.
41. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17(13):4550-7. Epub 2011/04/19. doi: 10.1158/1078-0432.CCR-11-0116 PMID: 21498393; PubMed Central PMCID: PMC3131487.
42. Di Mitri D, Azevedo RI, Henson SM, Libri V, Riddell NE, Macaulay R, et al. Reversible senescence in human CD4+CD45RA+CD27- memory T cells. J Immunol. 2011; 187(5):2093-100. Epub 2011/07/27. doi: 10.4049/jimmunol.1100978 PMID: 21788446.
43. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006; 211:214-24. Epub 2006/07/11. doi: 10.1111/j.0105-2896.2006.00391.x PMID: 16824130; PubMed Central PMCID: PMC1501075.
44. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008; 105(38):14342-6. Epub 2008/09/17. doi: 10.1073/pnas.0804105105 PMID: 18794521; PubMed Central PMCID: PMC2567214.
45. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett. 2010; 127(2):85-92. Epub 2009/10/13. doi: 10.1016/j.imlet.2009.09.009 PMID: 19818367; PubMed Central PMCID: PMC2808451.
46. Stonier SW, Ma LJ, Castillo EF, Schluns KS. Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood. 2008; 112(12):4546-54. Epub 2008/09/25. doi: 10.1182/blood-2008-05-156307 PMID: 18812469; PubMed Central PMCID: PMC2597127.
47. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010; 21(4):427-37. Epub 2009/11/13. doi: 10.1089/hum.2009.114 PMID: 19905893; PubMed Central PMCID: PMC2938363.
48. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011; 17(10):1290-7. Epub 2011/09/20. doi: 10.1038/nm.2446 PMID: 21926977; PubMed Central PMCID: PMC3192229.
49. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015; 3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127 PMID: 25212991.
50. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013; 19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330 PMID: 23620405; PubMed Central PMCID: PMC3804130.
51. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116(20):4099-102. Epub 2010/07/30. doi: blood-2010-04-281931 [pii]doi: 10.1182/blood-2010-04-281931 PMID: 20668228; PubMed Central PMCID: PMC2993617.
52. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005; 105(11):4247-54. Epub 2005/02/25. doi: 10.1182/blood-2004-11-4564 PMID: 15728125; PubMed Central PMCID: PMC1895037.